All In Biotech

Drug Trial Radar · NCT04900350

A Trial of AK117 (Anti-CD47) in Patients With Myelodysplastic Syndrome

A Phase I/II Trial of AK117 (Anti-CD47) in Patients With Higher-risk Myelodysplastic Syndrome

Last checked: Nov 19, 2026Latest source record: Mar 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

136

Actual

Start

Jun 18, 2021

Primary completion

Sep 2025

Study completion Dec 2025

Sponsor

Lead sponsor
AkesoIndustry
Sponsor type
Industry
First posted
May 25, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a open label, phase I/II study. All patients are diagnosed with higher-risk MDS, Eastern Cooperative Oncology Group (ECOG) performance status 0-2. The purpose of this study is to evaluate the safety and efficacy of AK117 + azacitidine in subjects with higher-risk MDS.

Conditions

  • Myelodysplastic Syndrome

Interventions

  • AK117Drug

    Subjects receive AK117 intravenously.

  • AzacitidineDrug

    Subjects receive Azacitidine subcutaneously.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of Complete Remission (CR)Time frame: Approximately 6 months
  2. Number of participants with adverse events (AEs)Time frame: Up to approximately 2 years.
  3. Duration of Complete Remission (DoCR)Time frame: Up to approximately 2 years.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Soochow University

    Suzhou, Jiangsu, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.